Analysis multivariate of survival and prognostic factors in a cohort of patients with hormone receptor-positive breast cancer.
Análisis multivariado de la supervivencia y los factores pronósticos de una cohorte de paciente con cáncer de mama receptor hormonal positivo.
Article Sidebar
PDF (Español (España))
FLIP
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Main Article Content
Objective: The main purpose of this investigation was to evaluate prognosis factors associated with the overall and desease free survival of hormone receptor-positive breast cancer. Methods: The data for this investigation was collected from the hospital Oncocare, from patients that were diagnosed with hormone receptor-positive breast cancer (stage I to IIIC) during the period of January 1st, 2003 to July 31st, 2012. This information was first used to construct survival curves using the Kaplan-Meier methods, then compared by using range logarithms, they were analysed using proportional range of regression by Cox. Results: In this investigation, a total of 387 patients were used, the mortality rate for the cohort was 7.24%, and relapses were 9.82%. The median age was 55.3 years old, and the median follow-up were 48.2 months. The clinical stage distribution were as it follows, stage I 10.85%, IIA 16.28%, IIB 17.05%, IIIA 22.74%, IIIB 19.12% and IIIC 13.95%; the HER2 receptors are positive by 13.7%. The percentage of patients that received neoadjuvant chemotherapy was 60.72%; 59.15% were type AC and 22.25% were type ACT. Additionally, 73.90% received adjuvant chemotherapy: type AC 44.91%, trastuzumab 14.7% and taxenes 23.25%. The response to neoadjuvant chemotherapy were: objective response 76.17%, complete 14.89%, partial 61.28 %; relapse were 9.82% (local 2.58%, regionals 1.29% and systematic 7.75%). Multivariate analysis also suggests that the number of positive lymph nodes, 10 or more, decrease desease free survival HR 2.30 (1.39-2.80). The clinical objective response, the tumour size, HER2 positive, positive hormonal receptors, age and clinical stage do not affect overall and desease free survival in the multivariate analysis. Conclusion: The desease free survival decreases with 10 or more positive lymph nodes. Other variables such as tumour size, clinical stage, age, HER2 positive and objective clinical response do not affect overall and desease free survival.
Downloads
Article Details
Instituto Nacional de Cancerología (INC), Instituto Geográfico Agustín Codazzi (IGAC). Atlas de mortalidad por cáncer en Colombia. 3ª ed. Bogotá: Imprenta Nacional de Colombia; 2010.
International Agency for Research on Cancer. Globocan 2008. IARC 2012 [citado 2012 sep 15]. Disponible en: http://globocan.iarc.fr/
Piñeros M, Sánchez R, Cendales R, et al. Características sociodemográficas, clínicas y de la atención de mujeres con cáncer de mama en Bogotá. Rev Colomb Cancerol 2008;12:181-90.
Schwartsmann G. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol 2001;19(18Suppl):118S-24S.
Piñeros M, Sánchez R, Cendales R, Perry F, Ocampo R. Patient delay among Colombian women with breast cancer. Salud Pública Mex 2009;51(5):372-80.
Instituto Nacional de Cancerología (INC). Anuario estadístico 2010. Bogotá: Impreso en Buenos y Creativos SAS; 2012.
Robledo JF, Caicedo JJ, De Antonio R. Análisis de supervivencia en una cohorte de 1.328 pacientes con carcinoma de seno. Rev Colomb Cir 2005;20(1):4-20.
Ospino R, Cendales R, Sánchez Z, Bobadilla I, Galvis J, Cifuentes J. Supervivencia en pacientes con cáncer de mama temprano tratadas con cirugía conservadora asociada a radioterapia en el Instituto Nacional de Cancerología. Rev Colomb Cancerol 2011;15(2):21-30.
Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO. Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res 2009;11(4):R44.
Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, et al. Breast carcinoma survival in Europe and the United States. Cancer 2004;100(4):715-22.
Giltnane JM, Moeder CB, Camp RL, Rimm DL. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 2009;115(11):2400-9.
Guerra MR, Mendonca GA, Bustamante-Teixeira MT, Cintra JR, Carvalho LM, Magalhaes LM. [Five-year survival and prognostic factors in a cohort of breast cancer patients treated in Juiz de Fora, Minas Gerais State, Brazil]. Cad Saude Publica 2009;25(11):2455-66.
Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thurlimann B, et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007;18(5):859-67.
Kim J, Lee J, Chang E, Suh K, Lee C, Jee J, et al. Prognostic factors in patients with stage ii/iii breast cancer treated with adjuvant extension of neoadjuvant chemotherapy: a retrospective cohort study with ten-years of follow-up data. J Breast Cancer 2011;14(1):39-45.
Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9(1):R6.
Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005;103(11):2241-51.
WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication Nº 48; 1979.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-312.
